Soluble E-cadherin as a serum biomarker in patients with HBV-related liver diseases.
|
| Abstract | OBJECTIVE: Substantial evidence indicates that serum sE-cadherin is a pivotal regulator that contributes to the initiation and development of various types of diseases. However, very little is known about the relationship between levels of serum sE-cadherin and HBV-related disorders. The overall goal of the study is to get a better insight into whether or not serum sE-cadherin is involved in HBV-related diseases. DESIGN AND METHODS: Serum levels of sE-cadherin and IFN-γ, from 113 patients with chronic hepatitis B, 101 patients with HBV-related cirrhosis, 75 patients with hepatocellular carcinoma and 125 healthy individuals were measured with commercial available sandwich ELISA kits. RESULTS: sE-cadherin values were significantly higher in patients compared to healthy control (p<0.0001). The levels of serum sE-cadherin were significantly positively correlated with the serum levels of IFN-γ, alanine transaminase and aspartate aminotransferase in chronic hepatitis B and cirrhosis patients. In hepatocellular carcinoma patients, serum sE-cadherin concentrations were only significantly positively correlated with the serum levels of ALT and AST. CONCLUSIONS:
|
|---|---|
| Authors | Bo Wang, Jingyi Liu, Yuan Xiong, Yan Yan, Bin Sun, Qing Zhao, Liang Duan, Pu Li, Yong Huang, Weixian Chen |
| Journal | Clinical biochemistry (Clin Biochem) Vol. 49 Issue 16-17 Pg. 1232-1237 (Nov 2016) ISSN: 1873-2933 [Electronic] United States |
| PMID | 27452182 (Publication Type: Journal Article) |
| Copyright | Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!